Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study
Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967
A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.
Venerito et al. sought to assess the safety and immunogenicity of the RZV in RA patients continuing to take their JAK inhibitor or biologic treatment, compared to healthy controls. The authors also highlighted that a single shot of RZV can lead to an anti-VZV immune response similar to healthy controls without the need to discontinue DMARDs. RZV reactogenicity is frequent but mild, and patients should be advised of that; nevertheless, this study detected no RA flare on a tight follow-up schedule
Keywords:
